诺瓦瓦克斯医药（NVAX）今日盘前大涨5.15%，引起投资者广泛关注。
这一显著涨幅主要源于美国食品和药物管理局（FDA）的最新决定。美国卫生与公共服务部长肯尼迪周三宣布，FDA已批准诺瓦瓦克斯医药、辉瑞和莫德纳的COVID疫苗供高风险患者使用。这一消息无疑为诺瓦瓦克斯医药带来了积极影响，推动其股价大幅上涨。
值得注意的是，FDA不仅批准了这些疫苗的使用，还终止了COVID疫苗的强制接种，结束了紧急状态。同时，FDA要求相关公司进行安慰剂对照试验。这些措施表明，尽管疫情已经得到控制，但对于高风险人群来说，COVID疫苗仍然具有重要意义。对于诺瓦瓦克斯医药而言，这一决定可能会为公司带来新的市场机遇，potentially boosting its revenue and market position in the long term。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.